Table 2 Selected ongoing clinical trials of inotuzumab ozogamicin for patients with relapsed/refractory B-cell ALL
Trial | Age (years) | ALL subtypes | Primary endpoint | Data presented or published | Trial Identifier |
|---|---|---|---|---|---|
INO + venetoclax + dexamethasone | 18+ | Ph-negative or Ph-positive | Maximum tolerated dose | Yes [53] | NCT05016947 |
INO + augmented BFM | 16–60 | Ph-negative | Maximum tolerated dose | No | NCT03962465 |
INO + blinatumomab + mini-hyper-CVD | 18+ | Ph-negative or Ph-positive | Response rate and overall survival | Yes [25] | NCT01371630 |
INO induction followed by blinatumomab (Alliance 041703) | 18+ | Ph-negative | Event-free survival | No | NCT03739814 |